MONOCLONAL-ANTIBODIES TO LEUCOSIALIN (CD43) INDUCE HOMOTYPIC AGGREGATION OF THE HUMAN MAST-CELL LINE HMC-1 - CHARACTERIZATION OF LEUCOSIALIN ON HMC-1 CELLS
S. Weber et al., MONOCLONAL-ANTIBODIES TO LEUCOSIALIN (CD43) INDUCE HOMOTYPIC AGGREGATION OF THE HUMAN MAST-CELL LINE HMC-1 - CHARACTERIZATION OF LEUCOSIALIN ON HMC-1 CELLS, Immunology, 82(4), 1994, pp. 638-644
CD43 (leucosialin, sialophorin) is the major sialoprotein of nearly al
l circulating leucocytes and has important biological activities in ce
llular differentiation and activation. Recently, the expression of CD4
3 has also been demonstrated on mast cells and basophils by flow cytom
etry. In order to further characterize mast cell/basophil leucosialin
we have investigated CD43 on the human mast cell line HMC-1, the human
basophilic precursor cell line KU-812, and the human promonocytic cel
l line U-937. The apparent molecular weights (MW) were 123,000 (HMC-1
and KU-812) and 144,000 (U-937) by Western blot analysis. Expression o
f CD43 on HMC-1 was down-regulated after stimulation with phorbol myri
state acetate (PMA). Three monoclonal antibodies (mAb) specific for hu
man CD43 induced homotypic mast cell line (HMC-1) aggregation in a sem
i-quantitative assay, a phenomenon that has not been described before
with mast cells. Monoclonal antibodies specific for seven other surfac
e antigens and an irrelevant mAb of the same isotype had no effect. Th
e level of aggregation was dependent on anti-CD43 mAb concentration, t
ime and temperature. Anti-leucosialin-induced aggregation of HMC-1 cel
ls was completely inhibited by mAb against CD11a (LFA-1) and CD18 (bet
a(2)-chain). Monoclonal antibody to CD54 (ICAM-1) partially inhibited
anti-CD43-induced homotypic aggregation, while anti-CD11b (CR3), anti-
CD11c (p 150, 95) and a control mAb had no inhibitory effect. We concl
ude that mast cell line CD43 antigen expression is differentially regu
lated during cell activation, and speculate that anti-CD43-induced hom
otypic aggregation of HMC-1 cells is closely associated with modulatio
n of beta(2)-integrins.